Shops Shoe Yell In Warwickshire Reviews Udxw0q8w1

Pipeline

Yell Shops Reviews Shoe In Warwickshire Novel compounds being developed for liver diseases

Intercept’s lead product, OCALIVA® (obeticholic acid), was granted accelerated approval by U.S. Food and Drug Administration (FDA) in May of 2016 for the treatment of primary biliary cholangitis, previously known as primary biliary cirrhosis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. OCALIVA is the first PBC therapy that targets the farnesoid X receptor (FXR), a key regulator of bile acid, inflammatory, fibrotic and metabolic pathways. For more information, please visit ocaliva.com.

Obeticholic acid (OCA) is also being evaluated for potential indications across a variety of additional chronic liver diseases, including nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and biliary atresia.

The pipeline chart above shows the target indications and current stages of development of all of our product candidates.

YOU ARE NOW leaving interceptpharma.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Intercept provides this link as a service to its website visitors. Intercept is not responsible for the content or the privacy policy of any third party websites.

Close this window to return to Intercept Pharmaceuticals’ site or click ‘Continue’ to proceed.

This website uses cookies. These cookies allow us to recognize, distinguish and count the number of visitors to our site, helping us to provide you with a good experience while browsing our website. Please check the box to acknowledge the use of cookies. To find out more about this, please see our privacy policy.